Prevalence of Clostridium Difficile-Associated Diarrhoea in Hospitalised Patients (Results of a Russian Prospective Multicentre Study)
| Autor: | Andrey V. Yakovenko, N V Bakulina, Vladimir Ivashkin, Elena A. Prokhorovich, Sergey V. Goryunov, Marina A. Sukhina, Natalia V. Dmitrieva, Stanislav V. Kazakov, Sergey V. Zhuravel, Tatyana R. Kameneva, Galina A. Klyasova, Aleksey A Samsonov, E. A. Belousova |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Microbiology (medical) medicine.medical_specialty 030106 microbiology Clostridium difficile toxin A Toxin B Clostridium difficile toxin B Toxin A Medical care Enzyme immunoassay lcsh:Infectious and parasitic diseases 03 medical and health sciences 0302 clinical medicine Clostridium Glutamate dehydrogenase Internal medicine Medicine lcsh:RC109-216 030212 general & internal medicine Hospitalised patients Original Research biology business.industry digestive oral and skin physiology Clostridium difficile-associated diarrheoa Antibiotic-associated diarrhoea Clostridium difficile biology.organism_classification Infectious Diseases business |
| Zdroj: | Infectious Diseases and Therapy Infectious Diseases and Therapy, Vol 7, Iss 4, Pp 523-534 (2018) |
| ISSN: | 2193-6382 2193-8229 |
| Popis: | Introduction The objective of the study was to evaluate the prevalence of Clostridium difficile-associated diarrhoea (CDAD) among hospitalised patients with antibiotic-associated diarrhoea (AAD) in general and by specific types of medical care and hospital units. Methods A prospective, cross-sectional, non-interventional, multicentre study. The main inclusion criteria were: patient age ≥ 18 years, hospital stay of at least 48 h, current antibiotic therapy or antibiotic therapy within the previous 30 days, loose stools (Bristol stool types 5–7 and stool frequency ≥ 3 within ≤ 24 consecutive hours or exceeding normal for the patient) and signed informed consent form. The stool sample was taken to the local (study site) microbiology laboratory for detection of glutamate dehydrogenase (GDH) and toxins A/B using enzyme immunoassay (EIA) stool test. Results From April 2016 to April 2017, a total of 1245 patients from 12 large hospitals were enrolled in the study. Data on 81 patients were excluded from the analysis for different reasons. Data on 1164 patients (45.2% males and 54.8% females) with a mean age of 54.9 years (range 18–95 years) were analysed. Length of hospitalisation was 2–188 days (median, 8 days). The EIA stool test showed CDAD-positive results in 21.7% (253/1164) patients. The patients were from surgery units (546/1164), internal medicine units (510/1164) and intensive care units (108/1164). The prevalence of CDAD among patients from surgery, internal medicine and intensive care units was 26.2, 17.8 and 17.6%, respectively. Oncology, gastroenterology, septic surgery, oncohaematology and general medical hospital units accounted for more than 75% of all patients included; the prevalence of CDAD by those hospital units was 11.3, 15.0, 39.2, 17.6, and 27.2%, respectively. The proportion of GDH-positive and toxin A/B-negative patients by the rapid stool test result was 16.8% (196/1164). The prevalence of CDAD varied widely between the hospitals (from 0 to 44.3%). Conclusions The prevalence of CDAD among hospitalised patients with AAD in this study was 21.7% (95% confidence interval: 14.8 and 28.7%). The percentage of CDAD varied widely between hospitals and by specific types of medical care and hospital units. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |